Neurocrine Biosciences
NBIX
NBIX
221 hedge funds and large institutions have $4.36B invested in Neurocrine Biosciences in 2017 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 85 increasing their positions, 72 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
10.06% more ownership
Funds ownership: 97.64% → 107.69% (+10%)
1% more funds holding
Funds holding: 218 → 221 (+3)
22% less call options, than puts
Call options by funds: $16.7M | Put options by funds: $21.5M
Holders
221
Holding in Top 10
7
Calls
$16.7M
Puts
$21.5M
Top Buyers
| 1 | +$247M | |
| 2 | +$140M | |
| 3 | +$79.8M | |
| 4 |
HM
HealthCor Management
New York
|
+$61M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.3M |
Top Sellers
| 1 | -$44.2M | |
| 2 | -$39M | |
| 3 | -$28.3M | |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$28.2M |
| 5 |
Jennison Associates
New York
|
-$15.1M |